Table 3 DPP-4 inhibitors and cardiovascular risk: ongoing studies (adapted from[8])
From: Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment
Sitagliptin | TECOS: Trial Evaluating Cardiovascular Outcomes with Sitagliptin |
Saxagliptin | SAVOR: Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial |
Alogliptin | EXAMINE: Examination of Cardiovascular Outcomes: Alogliptin vs Standard of Care in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome |
Linagliptin | CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients with Type 2 Diabetes |